Table 1 Demographic data of patients with dialysis-dependent CKD by quartile of circulating FGF23 levels
Fibroblast growth factor 23, RU/mL | |||||
|---|---|---|---|---|---|
|  | Q1 [203.2–779.7] | Q2 [1090–3585] | Q3 [3785–6785] | Q4 [6835–27360] | P-value |
Demographic and clinical characteristics | |||||
 Age (years) | 64.6 ± 10.6 | 68.6 ± 14.1 | 51.3 ± 22.4 | 59.0 ± 11.8 | 0.149 |
 Male sex (n, %) | 6 (75.0) | 3 (33.3) | 5 (62.5) | 3 (37.5) | 0.264 |
 BMI (kg/m2) | 24.3 ± 4.8 | 21.2 ± 4.4 | 21.3 ± 2.6 | 22.2 ± 3.1 | 0.344 |
 SBP (mmHg) | 136.4 ± 26.4 | 139.0 ± 13.8 | 122.8 ± 20.7 | 114.8 ± 23.1 | 0.088 |
 DBP (mmHg) | 78.1 ± 12.0 | 71.4 ± 18.9 | 76.5 ± 22.1 | 67.4 ± 11.4 | 0.568 |
Medical history (n, %) | |||||
 DM | 2 (25.0) | 1 (11.1) | 3 (37.5) | 1 (12.5) | 0.522 |
 Hypertension | 7 (87.5) | 8 (88.8) | 5 (62.5) | 6 (75.0) | 0.522 |
 Current smokers | 2 (25.0) | 0 (0.0) | 1 (12.5) | 1 (12.5) | 0.707 |
 MI | 1 (12.5) | 1 (11.1) | 0 (0.0) | 2 (25.0) | 0.235 |
 Ischemia | 2 (25.0) | 0 (0.0) | 0 (0.0) | 1 (12.5) | 0.235 |
 LVH | 4 (50.0) | 2 (22.2) | 5 (62.5) | 4 (50.0) | 0.387 |
 Previous KT | 3 (37.5) | 2 (22.2) | 3 (37.5) | 5 (62.5) | 0.403 |
Laboratory measurements | |||||
 Cholesterol (ng/mL) | 148.3 ± 38.6 | 141.7 ± 26.7 | 147.1 ± 29.0 | 151.6 ± 25.0 | 0.922 |
 Calcium (ng/mL) | 9.0 ± 0.3 | 8.8 ± 0.4 | 9.1 ± 0.5 | 9.0 ± 0.6 | 0.747 |
 Phosphorus (ng/mL) | 3.9 ± 0.9 | 4.3 ± 1.2 | 4.3 ± 1.4 | 4.9 ± 1.2 | 0.471 |
 CaxP | 35.1 ± 7.8 | 38.0 ± 10.4 | 39.3 ± 12.6 | 43.2 ± 9.5 | 0.467 |
 25-Hydroxyvitamin D (ng/mL) | 9.9 ± 3.1 | 9.3 ± 3.0 | 11.2 ± 4.4 | 8.3 ± 3.0 | 0.412 |
 Parathyroid hormone (pg/mL) | 350.4 ± 138.4 | 301.4 ± 199.0 | 475.5 ± 251.2 | 406.8 ± 242.3 | 0.444 |
 sKL (ng/mL) | 0.4 ± 0.2 | 0.3 ± 0.1 | 0.5 ± 0.3 | 0.3 ± 0.1 | 0.189 |
Dialysis-related parameters | |||||
 Dialysis vintage (months) | 95.4 ± 81.5 | 58.2 ± 59.3 | 59.8 ± 50.4 | 100 ± 100 | 0.536 |
 Serum creatinine (mg/dL) | 6.4 ± 1.3 | 7.3 ± 2.2 | 9.1 ± 2.7 | 7.7 ± 1.9 | 0.096 |
 Serum albumin (g/dL) | 4.3 ± 0.3 | 3.9 ± 0.3 | 4.2 ± 0.6 | 3.9 ± 0.4 | 0.211 |
 Kt/V | 1.7 ± 0.2 | 1.6 ± 0.3 | 1.6 ± 0.3 | 1.6 ± 0.3 | 0.757 |
 eGFR (ml/min/1.73m2) | 8.4 ± 2.4 | 6.5 ± 3.0 | 6.5 ± 4.2 | 6.3 ± 2.0 | 0.447 |
Medication | |||||
Anti-hypertensive drugs | |||||
 ACEi/ARB (%) | 1 (12.5) | 3 (33.3) | 4 (50.0) | 1 (12.5) | 0.260 |
 Beta-blocker (%) | 1 (12.5) | 5 (55.5) | 4 (50.0) | 4 (50.0) | 0.268 |
 Diuretics (%) | 2 (25.0) | 0 (0.0) | 0 (0.0) | 1 (12.5) | 0.235 |
Anti-arrhythmics drugs | |||||
 Amiodarone (%) | 0 (0.0) | 0 (0.0) | 1 (12.5) | 0 (0.0) | 0.359 |
Bone-mineral metabolism drugs | |||||
 Calcium chelators (%) | 1 (12.5) | 6 (66.6) | 5 (62.5) | 5 (62.5) | 0.091 |
 Sevelamer (%) | 3 (37.5) | 4 (44.4) | 3 (37.5) | 3 (37.5) | 0.989 |
 Lantanum carbonate (%) | 1 (12.5) | 1 (11.1) | 5 (62.5) | 4 (50.0) | 0.054 |
 Cinacalcet (%) | 1 (12.5) | 3 (33.3) | 5 (62.5) | 4 (50.0) | 0.349 |
 Paricalcitol (%) | 7 (87.5) | 5 (55.5) | 5 (62.5) | 4 (50.0) | 0.381 |
 Colecalciferol (%) | 1 (12.5) | 1 (11.1) | 0 (0.0) | 1 (12.5) | 0.785 |
 Parathyroidectomy (%) | 0 (0.0) | 2 (22.2) | 1 (12.5) | 1 (12.5) | 0.620 |
Electrocardiogram parameters | |||||
 HR (bpm) | 78.8 ± 9.3 | 81.8 ± 13.3 | 85.8 ± 15.8 | 83.4 ± 8.3 | 0.702 |
 SDANN | 83.4 ± 30.2 | 57.6 ± 15.1 | 76.0 ± 28.0 | 78.9 ± 15.5 | 0.153 |
 SDNN | 37.3 ± 16.0 | 33.8 ± 13.5 | 43.0 ± 13.5 | 37.5 ± 17.5 | 0.682 |
 RMSSD | 37.8 ± 24.6 | 45.6 ± 23.1 | 48.8 ± 13.4 | 41.5 ± 20.8 | 0.769 |
 TpTe interval (ms) | 85.5 ± 17.3 | 108.9 ± 39.7 | 97.1 ± 19.8 | 136.0 ± 45.6 | 0.029 |